Long-term management of patients with end-stage lung diseases

Domenica Federica Briganti, Frank D'Ovidio

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Long-term management of end-stage lung disease differs from interstitial lung disease to chronic obstructive pulmonary disease to cystic fibrosis to pulmonary vascular disease. The management includes pharmacological therapy that is disease specific such as antibiotic therapy for cystic fibrosis, antifibrotic drugs in idiopathic pulmonary fibrosis; long-acting beta-agonists, long-acting muscarinic antagonist, and inhaled corticosteroids in chronic obstructive pulmonary disease; and vasodilators in pulmonary arterial hypertension. Moreover, non-pharmacological therapy is essential in the treatment of these diseases, in particular, rehabilitation and supportive therapy, which are necessary in all end-stage lung diseases and specific intervention such as non-invasive ventilation in chronic obstructive pulmonary disease and cystic fibrosis, surgical therapy in chronic obstructive pulmonary disease, and airway clearance in cystic fibrosis. The goal is not only to prolong survival, but it is fundamental to keep patients in good general conditions for transplantation. Transplantation, indeed, remains the only therapeutic option that could prolong survival in patients with terminal lung disease when medical or surgical therapies are not available or not effective anymore.

Original languageEnglish
JournalBest Practice and Research: Clinical Anaesthesiology
DOIs
Publication statusAccepted/In press - 2017
Externally publishedYes

Fingerprint

Lung Diseases
Cystic Fibrosis
Chronic Obstructive Pulmonary Disease
Therapeutics
Transplantation
Noninvasive Ventilation
Idiopathic Pulmonary Fibrosis
Muscarinic Antagonists
Survival
Interstitial Lung Diseases
Vasodilator Agents
Vascular Diseases
Pulmonary Hypertension
Adrenal Cortex Hormones
Rehabilitation
Pharmacology
Anti-Bacterial Agents
Pharmaceutical Preparations

Keywords

  • Chronic obstructive pulmonary disease
  • Cystic fibrosis
  • Lung disease
  • Pulmonary fibrosis
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Long-term management of patients with end-stage lung diseases. / Briganti, Domenica Federica; D'Ovidio, Frank.

In: Best Practice and Research: Clinical Anaesthesiology, 2017.

Research output: Contribution to journalArticle

@article{2a1c406d138f4679afea78e00f7228ea,
title = "Long-term management of patients with end-stage lung diseases",
abstract = "Long-term management of end-stage lung disease differs from interstitial lung disease to chronic obstructive pulmonary disease to cystic fibrosis to pulmonary vascular disease. The management includes pharmacological therapy that is disease specific such as antibiotic therapy for cystic fibrosis, antifibrotic drugs in idiopathic pulmonary fibrosis; long-acting beta-agonists, long-acting muscarinic antagonist, and inhaled corticosteroids in chronic obstructive pulmonary disease; and vasodilators in pulmonary arterial hypertension. Moreover, non-pharmacological therapy is essential in the treatment of these diseases, in particular, rehabilitation and supportive therapy, which are necessary in all end-stage lung diseases and specific intervention such as non-invasive ventilation in chronic obstructive pulmonary disease and cystic fibrosis, surgical therapy in chronic obstructive pulmonary disease, and airway clearance in cystic fibrosis. The goal is not only to prolong survival, but it is fundamental to keep patients in good general conditions for transplantation. Transplantation, indeed, remains the only therapeutic option that could prolong survival in patients with terminal lung disease when medical or surgical therapies are not available or not effective anymore.",
keywords = "Chronic obstructive pulmonary disease, Cystic fibrosis, Lung disease, Pulmonary fibrosis, Pulmonary hypertension",
author = "Briganti, {Domenica Federica} and Frank D'Ovidio",
year = "2017",
doi = "10.1016/j.bpa.2017.07.007",
language = "English",
journal = "Bailliere's Best Practice and Research in Clinical Anaesthesiology",
issn = "1753-3740",
publisher = "Bailliere Tindall Ltd",

}

TY - JOUR

T1 - Long-term management of patients with end-stage lung diseases

AU - Briganti, Domenica Federica

AU - D'Ovidio, Frank

PY - 2017

Y1 - 2017

N2 - Long-term management of end-stage lung disease differs from interstitial lung disease to chronic obstructive pulmonary disease to cystic fibrosis to pulmonary vascular disease. The management includes pharmacological therapy that is disease specific such as antibiotic therapy for cystic fibrosis, antifibrotic drugs in idiopathic pulmonary fibrosis; long-acting beta-agonists, long-acting muscarinic antagonist, and inhaled corticosteroids in chronic obstructive pulmonary disease; and vasodilators in pulmonary arterial hypertension. Moreover, non-pharmacological therapy is essential in the treatment of these diseases, in particular, rehabilitation and supportive therapy, which are necessary in all end-stage lung diseases and specific intervention such as non-invasive ventilation in chronic obstructive pulmonary disease and cystic fibrosis, surgical therapy in chronic obstructive pulmonary disease, and airway clearance in cystic fibrosis. The goal is not only to prolong survival, but it is fundamental to keep patients in good general conditions for transplantation. Transplantation, indeed, remains the only therapeutic option that could prolong survival in patients with terminal lung disease when medical or surgical therapies are not available or not effective anymore.

AB - Long-term management of end-stage lung disease differs from interstitial lung disease to chronic obstructive pulmonary disease to cystic fibrosis to pulmonary vascular disease. The management includes pharmacological therapy that is disease specific such as antibiotic therapy for cystic fibrosis, antifibrotic drugs in idiopathic pulmonary fibrosis; long-acting beta-agonists, long-acting muscarinic antagonist, and inhaled corticosteroids in chronic obstructive pulmonary disease; and vasodilators in pulmonary arterial hypertension. Moreover, non-pharmacological therapy is essential in the treatment of these diseases, in particular, rehabilitation and supportive therapy, which are necessary in all end-stage lung diseases and specific intervention such as non-invasive ventilation in chronic obstructive pulmonary disease and cystic fibrosis, surgical therapy in chronic obstructive pulmonary disease, and airway clearance in cystic fibrosis. The goal is not only to prolong survival, but it is fundamental to keep patients in good general conditions for transplantation. Transplantation, indeed, remains the only therapeutic option that could prolong survival in patients with terminal lung disease when medical or surgical therapies are not available or not effective anymore.

KW - Chronic obstructive pulmonary disease

KW - Cystic fibrosis

KW - Lung disease

KW - Pulmonary fibrosis

KW - Pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=85030460368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030460368&partnerID=8YFLogxK

U2 - 10.1016/j.bpa.2017.07.007

DO - 10.1016/j.bpa.2017.07.007

M3 - Article

JO - Bailliere's Best Practice and Research in Clinical Anaesthesiology

JF - Bailliere's Best Practice and Research in Clinical Anaesthesiology

SN - 1753-3740

ER -